| Literature DB >> 35126599 |
Mengnan Liu1,2, Gang Luo1, Tianzhu Liu3, Tingfu Yang1, Raoqiong Wang2,4, Wei Ren5, Ping Liu1, Xiaoling Lai1, Hua Zhou2,6,7, Sijin Yang1,2.
Abstract
BACKGROUND: Our previous studies have demonstrated a protective role of Zhilong Huoxue Tongyu capsule in atherosclerosis (AS); however, the molecular mechanisms are unclear.Entities:
Year: 2022 PMID: 35126599 PMCID: PMC8813228 DOI: 10.1155/2022/3981350
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1The effect of medicated serum of Zhilong Huoxue Tongyu capsule on HCAECs viability. HCAECs were hatched with different concentrations of medicated serum of Zhilong Huoxue Tongyu capsule for 24 h (0, 5, 10, 15, 20, and 25%). The cell viability was detected by CCK-8 Kit. Data of four independent samples were shown as mean ± SE. P < 0.05. The medicated serum of Zhilong Huoxue Tongyu capsule relieves the pyroptosis of HCAECs induced by ox-LDL in vitro.
Figure 2The medicated serum of Zhilong Huoxue Tongyu capsule relieves the pyroptosis of HCAECs induced by ox-LDL in vitro. HCAECs were treated with 50 nM ox-LDL for 24 h to induce atherosclerosis cell models and then incubated with 200 μL Zhilong Huoxue Tongyu capsule medicated serum. (a, b) The rate of pyroptosis was determined by flow cytometry assays. (c) The LDH content was detected using commercial kit. (d) The relative mRNA levels of NLRP3, ASC, Caspase 1, IL-1β, and IL-18 were detected by qRT-PCR assay. The data were expressed after being normalized to β-actin. Data of three independent samples were shown as mean ± SE. P < 0.05.
Figure 3NLRP3 binds to miR-30b-5p. (a) HCAECs were treated with 50 nM ox-LDL for 24 h to induce atherosclerosis cell models and then incubated with 200 μL Zhilong Huoxue Tongyu capsule medicated serum. The level of miR-30b-5p was detected by qRT-PCR assay. The data were expressed after being normalized to U6. (b) The binding sites of miR-30b-5p and NLRP3 were forecasted via the bioinformatics website. NLRP3 wild-type plasmids and mutant plasmids were constructed. (c) NLRP3 wild-type and mutant plasmids were constructed into pGL3-Basic luciferase vector to produce luciferase reporter plasmids. HCAECs were transfected with the plasmids and then were cotransfected with miR-NC or miR-30b-5p mimic with Lipofectamine 2000; after cells were transfected for 48 h, the direct interaction of NLRP3 and miR-30b-5p was verified by luciferase reporter experiment. (d) The relative mRNA level of NLRP3 was detected by qRT-PCR assay after HCAECs were transfected with miR-30b-5p mimic or miR-30b-5p inhibitor. The data were expressed after being normalized to β-actin. Data of three independent samples were shown as mean ± SE. P < 0.05.
Figure 4The medicated serum of Zhilong Huoxue Tongyu capsule alleviates the pyroptosis of HCAECs induced by ox-LDL through miR-30b-5p/NLRP3. HCAECs were treated with 50 nM ox-LDL for 24 h to induce atherosclerosis cell models and then incubated with 200 μL Zhilong Huoxue Tongyu capsule medicated serum. Next, cells were transfected with 5 nM miR-30b-5p-mimic and miR-30b-5p-inhibitor, respectively. (a, b) The rate of pyroptosis was determined by flow cytometry assays. (c) The LDH content was detected using commercial kit. (d) The relative mRNA levels of NLRP3, ASC, Caspase 1, IL-1β, and IL-18 were detected by qRT-PCR assay. The data were expressed after being normalized to β-actin. Data of three independent samples were shown as mean ± SE. P < 0.05 compared to control group. #P < 0.05 compared to ox-LDL group. &PP < 0.05 compared to ox-LDL + MS. MS: medicated serum.